01.19.24 -- Tips For Partnering With Big Pharma

We spend a lot of time talking with our guests about building biotech companies. On this episode of Business of Biotech, we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. Dr. Leonard shares the foundational elements of a biotech community, particularly around rapidly advancing technologies such as CRISPR, and what biotech ecosystems offer emerging biotechs in terms of resources, IP, and support.

Adept CRO communication doesn’t just indicate the vendor’s ability to deliver a thoughtful bid; it demonstrates their ability to analyze, operationalize, and optimize a plan.

Get a deeper look into how drug lipophilicity has evolved over time, its impact on drug development, and the need for new technology to enable new more complex drugs.

Review key factors for building a reliable CLD strategy and learn how the right CDMO can help you achieve the high quality, high yield, and speed needed to successfully bring a biologic to market.